Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
4.54M
-
Number of holders
-
27
-
Total 13F shares, excl. options
-
3.31M
-
Shares change
-
+1.9M
-
Total reported value, excl. options
-
$35.6M
-
Value change
-
+$20.4M
-
Number of buys
-
14
-
Number of sells
-
-4
-
Price
-
$10.75
Significant Holders of Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) as of Q3 2024
31 filings reported holding CDTX - Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2024.
Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) has 27 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.31M shares
of 4.54M outstanding shares and own 72.87% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (703K shares), RA CAPITAL MANAGEMENT, L.P. (703K shares), BVF INC/IL (703K shares), Monashee Investment Management LLC (369K shares), Checkpoint Capital L.P. (182K shares), VANGUARD GROUP INC (181K shares), RENAISSANCE TECHNOLOGIES LLC (97.8K shares), ALETHEA CAPITAL MANAGEMENT, LLC (79.9K shares), 5AM Venture Management, LLC (56.7K shares), and GEODE CAPITAL MANAGEMENT, LLC (52.9K shares).
This table shows the top 27 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.